Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: SCYX =MC 73 M / Cash 35 M / NDA filing in 2H + 3 Drugs In P3

No earlier versions found for this Subject.

Return to SCYX =MC 73 M / Cash 35 M / NDA filing in 2H + 3 Drugs In P3

MCap $73 Million / Cash $35 Million / NDA submission for BIG drug this or next Q / Another 3 Drugs in Phase 3 = One of the CHEAPEST biotech in the entire sector a potential 10 Bagger here guys .GL

Scynexis (SCYX)

Market Cap $73 Million
Cash $35 Million
Price $7.40

Shares Out 9.9 Million

Presentation

d1io3yog0oux5.cloudfront.net

Scynexis' lead drug scores in vaginal yeast infection trial
endpts.com

Ibrexafungerp,if approved, could end up as the only oral alternative to fluconazole approved for acute VVC infections, although Mycovia is testing another therapy, VT-1161, for patients with recurrent VVC, Needham’s Alan Carr wrote in a note, adding that he expects ibrexafungerp to launch in 2021.

“Our data suggest 15% of pts return to their physician because existing treatments are inadequate…physician interest in a new drug is high and we estimate even modest (25%) penetration of the second-line setting generates peak sales (for ibrexafungerp) of over $450M.”